Phase II study of XELIRI and High-dose bevacizumab as second-line therapy in patients with metastatic colorectal cancer
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000008425
- Lead Sponsor
- Yokohama Rosai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 38
Not provided
1.History of severe allergy 2.Pregnant or lactating women or women of childbearing potential 3.Severe infection disease 4.HBsAg(+) or HBV-DNA(+) 5.Previous history of hemoptysis or evidence of bleeding diathesis or coagulopathy 6. Metastases to the CNS 7. Complication of inflammation or active gastrointestinal 8. Non-healing wound 9. anti-platelets therapy 10. History of thrombosis or cerebrovascular disorder 11. Uncontrolled high blood pressure 12. Serious heart disease 13. Uncontrolled diarrhea 14.Paresis of intestine or intestinal obstruction 15.Interstitial pneumonitis 16.Serious peritoneal fluid and pericardial fluid 17.Multiple primary cancer which heals within five years 18. receiving atazanavir sulfate 19. requiring steroid drug 20.Have the homo and double heterozygote of *6,*28. 21. Other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method